ESTRO 2025 - Abstract Book

S863

Clinical - Gynaecology

ESTRO 2025

Figure 2

Conclusion: This study demonstrates the prognostic value of blood-based inflammatory markers in stratifying risk and predicting treatment outcomes in LACC patients. The use of an unsupervised clustering approach, such as AHC, effectively identifies patient subgroups with significant differences in local control and disease-free survival, offering a potential tool for personalized treatment planning.

Keywords: chemoradiation, brachytherapy

3899

Proffered Paper Chemoradiotherapy combined with image-guided adaptive brachytherapy for locally advanced cervical cancer results in sustained outcomes beyond 5 years Primoz Petric 1,2 , Alina Sturdza 3 , Stefan Ecker 3 , Maximilian Schmid 3 , Christian Kirisits 3 , Jacob C Lindegaard 4 , Ina M Schulz-Jurgenliemk 5 , Kari Tanderup 4 , Barbara Šegedin 1 , Kjersti Bruheim 6 , Fleur Huang 7 , Bhavana Rai 8 , Elzbieta van der Steen-Banasik 9 , Maarit Anttila 10 , Marit Sundset 11 , Richard Pötter 3 1 Department of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. 2 Department of Radiation Oncology, Zürich University Hospital, Zürich, Switzerland. 3 Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 4 Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. 5 Department of Radiation Oncology, University Medical Centre Utrecht, Utrecht, Netherlands. 6 Department of Oncology, Oslo University Hospital, Oslo, Norway. 7 Department of Oncology, Cross Cancer Institute and University of Alberta, Edmonton, Canada. 8 Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. 9 Department of Radiotherapy, Radiotherapiegroep Arnhem, Arnhem, Netherlands. 10 Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland. 11 Clinic of Oncology and Women's Clinic, St. Olavs Hospital, Trondheim, Norway Purpose/Objective: The EMBRACE-I study (1) demonstrated unprecedented 5-year local control across all stages following chemoradiotherapy (CRT) and MRI-based image-guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer. This was associated with high pelvic control and survival. Severe radiation-induced morbidity was limited. However, long-term oncological outcomes after CRT/IGABT remain largely unknown. We aimed to analyse long-term overall survival, and local, pelvic, and systemic control in an EMBRACE-I sub-cohort with available extended follow-up (FU) data.